Adults aged 55–65 accounted for 29% of prescriptions, followed by seniors 65+ (26%)|chemist4u|CC BY 2.0
Prescriptions for GLP-1 drugs commonly taken for diabetes, heart risks and obesity surged roughly 10% almost all over America last year, finds health analytics company PurpleLab.
The data is based on $7.5 billion in health insurance claims.
It shows that 23 states had double-digit growth, with Rhode Island (67.8%), Massachusetts (48%), and New Jersey (35.8%) leading the trend.
However, six states, including Arkansas and Louisiana, saw declines.
Adults aged 55–65 accounted for 29% of prescriptions, followed by seniors 65+ (26%).
Most prescriptions were for commercially insured patients, with Medicaid and Medicare patients making up 9% and 17%, respectively.
What anti-obesity drugs are Americans using?
The medications include Novo Nordisk drugs treating diabetes, Ozempic and weight loss, Wegovy, Eli Lilly’s Mounjaro, and its recently approved anti-obesity drug, Zepbound.